Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer's disease in bladder cancer patients

Alzheimer's disease (AD) affects one in ten people older than 65 years. Thus far, there is no cure or even disease-modifying treatment for this disease. The immune system is a major player in the pathogenesis of AD. Bacillus Calmette-Guérin (BCG), developed as a vaccine against tuberculosis, mo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2019-11, Vol.14 (11), p.e0224433-e0224433
Hauptverfasser:	Gofrit, Ofer N, Klein, Benjamin Y, Cohen, Irun R, Ben-Hur, Tamir, Greenblatt, Charles L, Bercovier, Hervé
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Aged Aged, 80 and over Alzheimer Disease - complications Alzheimer Disease - drug therapy Alzheimer Disease - pathology Alzheimer's disease Animals Bacillus Bacillus Calmette-Guerin vaccine BCG BCG Vaccine - administration & dosage Biology and Life Sciences Bladder Bladder cancer Cancer Cancer therapies Clinical trials Cytokines Data collection Dementia Diagnosis Disease Progression Disease-Free Survival Female Females Humans Immune system Incidence Invasiveness Kaplan-Meier Estimate Male Males Medical diagnosis Medical treatment Medicine and Health Sciences Mice Microbiota Middle Aged Movement disorders Muscles Mycobacterium bovis - genetics Mycobacterium bovis - immunology Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neurodegenerative diseases Neurotoxicity Parkinson's disease Pathogenesis Pathology Population Regression analysis Regression models Research and Analysis Methods Risk Survival analysis Treatment Outcome Tuberculosis Urinary Bladder Neoplasms - complications Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology Urology Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!